GlassScriptPhysician profile
George T Matsuda
NPI 1144220815
$7,791.21
in general payments reported to CMS, 2019-2025
43 companies · $741 in 2025
The $741 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,715 · 2020: $859 · 2021: $1,227 · 2022: $859 · 2023: $704 · 2024: $685 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059 · Education: $71.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.32 |
| Education | $71.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,090.69 | 2019-2024 | |
| Covidien LP | $1,000.00 | 2019 | |
| Intuitive Surgical, INC. | $353.35 | 2019 | |
| Astellas Pharma US INC | $309.59 | 2023-2025 | Veozah |
| Medicines360 | $275.00 | 2020 | |
| Mayne Pharma Commercial LLC | $264.08 | 2021-2025 | |
| Myovant Sciences INC. | $264.03 | 2021-2022 | |
| Pfizer INC. | $252.95 | 2021-2024 | |
| Exeltis, USA INC. | $242.24 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $204.65 | 2023-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $201.81 | 2019-2025 | |
| Amag Pharmaceuticals, INC. | $198.90 | 2019 | |
| Millicent US INC | $194.90 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Merck Sharp & Dohme LLC | $162.28 | 2019-2025 | Gardasil 9 |
| Organon LLC | $159.68 | 2021-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Matsuda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.